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Background: RV dysfunction contributes to significant morbidity and is an important prognostic indicator in dilated cardiomyopathy (DCM) 
patients with LV systolic dysfunction (LVSD). Effect of Sildenafil on pulmonary hemodynamics and RV systolic dysfunction in DCM patients is largely is 
unknown.
Methods: Adult patients with heart failure due to DCM (LVEF <35%) and evidence of RV systolic dysfunction (EF<45%) on stable medical therapy 
were eligible. Baseline echocardiogram, MUGA (to confirm RV and LV EF), functional testing, coronary angiogram and right heart catheterization 
were performed. Acute hemodynamic response was tested by repeat right heart catheterization after on table 100 mg oral Sildenafil administration. 
Sildenafil was continued for 12 weeks after which functional status (NYHA class, 6MWT, naughton tread mill protocol) and LV and RVEF (by MUGA) 
were reassessed and compared to baseline parameters. Patients with valvular and ischemic heart disease were excluded. 
Results: 21 patients (mean age 45.75±17.3 years, 90.5% males) were included. Mean NYHA class was 2.7, 23.8% had hypertension and 14.3% 
were diabetic. Compared to baseline parameters, after Sildenafil administration, there was a significant reduction in PASP (46.19±15.82 mmHg vs 
32.1±12.51 mmHg), mean PAP (31.76±10.44 mmHg vs 21.14±7.95 mmHg), PADP (22.71±9.33 mmHg vs 14.57±6.6mmHg), PCWP (19.33±7.31 
mmHg vs 14.33±7.79 mmHg), PVR (2.85±1.74 . Woods unit (WU) vs 1.56±0.838 WU) and PVR/SVR ratio (0.154±0.08 vs. 0.101±0.05) {all p 
values<0.05} . Three months follow-up data was available on 11 patients. Compared to baseline, statistically significant improvement was noted in 
RVEF (33.36 ± 6.62 vs 51.91±11.16), tricuspid annular excursion (1.52 ± 0.29mm vs 1.94 ± 0.22mm), 6-minute walk distance (428.45 ± 32.32m 
vs 475.73 ± 35.66m) and functional status (4.27 ± 1.27METs vs 7.09 ± 1.44METs) {all p values <0.05}. Improvement in RVEF was independent of 
baseline PASP (>50mmHg vs <50mmHg).
Conclusions: Sildenafil improves pulmonary hemodynamics acutely and RV systolic dysfunction at 12 weeks in DCM patients with biventricular 
systolic dysfunction though study was limited by small number and high dropout rate
